

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>Kim Na Yeon</u>			2. Issuer Name and Ticker or Trading Symbol <u>NeuroBo Pharmaceuticals, Inc. [ NRBO ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>12/30/2019</u>			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
<u>C/O NEUROBO PHARMACEUTICALS, INC.</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)					
<u>177 HUNTINGTON AVENUE, SUITE 1700</u>								
(Street)								
<u>BOSTON</u>	<u>MA</u>	<u>02115</u>						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	12/30/2019		A		4,335,800	A	(1)(4)	4,335,800	I	Held by The E&Healthcare Investment Fund II <sup>(5)</sup>
Common Stock	12/30/2019		A		1,121,190	A	(2)(4)	1,121,190	I	Held by The E&Healthcare Investment Fund No. 6 <sup>(5)</sup>
Common Stock	12/30/2019		A		1,864,799	A	(3)(4)	1,864,799	I	Held by The E&Healthcare Investment Fund No. 7 <sup>(5)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Explanation of Responses:

- Received in connection with the closing of the merger of GR Merger Sub Inc., a wholly-owned subsidiary of the Issuer, with and into NeuroBo Therapeutics, Inc. (formerly NeuroBo Pharmaceuticals, Inc.) ("NeuroBo") on December 30, 2019 (the "Merger"), in exchange for 3,500,000 shares of common stock issued upon the conversion of Series A preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 293,019 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund II.
- Received in connection with the closing of the Merger in exchange for 900,000 shares of common stock issued upon conversion of Series B preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 80,833 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund No. 6.
- Received in connection with the closing of the Merger in exchange for 1,500,000 shares of common stock issued upon the conversion of Series B preferred stock of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, and 131,353 shares of common stock issued upon conversion of convertible promissory notes of NeuroBo, which conversion occurred immediately prior to the closing of the Merger, held by The E&Healthcare Investment Fund No. 7.
- In connection with the closing of the Merger, each share of NeuroBo common stock was exchanged for 1.1431 shares of the Issuer's common stock.
- Ms. Kim is the Chief Executive Officer of E&I Investment. E&Investment is the sole general partner of The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7, and has voting power over the shares held by The E&Healthcare Investment Fund II, The E&Healthcare Investment Fund No. 6 and The E&Investment Healthcare Fund No. 7. Ms. Kim is the Chief Executive Officer of E&Investment, and as such has voting and investment control over the shares held by E&Investment and its affiliated funds. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein.

Remarks:

All share and per share amounts of the Issuer's common stock and stock options reported in this Form 4 reflect the 10,000-for-1 reverse stock split of the NeuroBo's common stock effected on August 13, 2019.

/s/ Na Yeon Kim

01/02/2020

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

